Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMAT - ultrafast tomography for coronary artery disease -- Ignore unavailable to you. Want to Upgrade?

To: stock bull who wrote (2412)	4/23/1998 10:38:00 AM
From: GREATMOOD	Read Replies (1) \| Respond to of 3725

Imatron Receives ISO 9001 Registration; Grants Imatron Enhanced Access to International Markets SO. SAN FRANCISCO, Calif.--(BUSINESS WIRE)--April 23, 1998-- Imatron Inc. (Nasdaq: IMAT) said today that it has received ISO 9001 Quality Management System registration for the design, manufacture and service of its Ultrafast CT(R) scanners. This approval, completed by National Quality Assurance, U.S.A., will require the Company to continually maintain its quality system to the standards set forth by the International Organization for Standardization. This registration will grant Imatron access to those international markets where ISO compliance is now mandatory. "ISO 9001 registration is a major achievement for Imatron. The hard work and dedication of our employees resulted in thorough refinement and update of our quality system required to meet the ISO 9001 standard," commented S. Lewis Meyer, Imatron President and CEO. "Imatron's achievement underscores our commitment to addressing customer requirements, product improvement, organizational quality, and regulatory compliance. Our ISO 9001 registration follows receipt of the CE Mark last year qualifying Imatron's Ultrafast CT scanner for importation into Europe," Mr. Meyer added. ISO quality guidelines involve all the operational areas of a business including sales, contract management, engineering, manufacturing, quality assurance, service, and customer service. Maintaining the ISO 9001 registration requires continuous improvements, on a company-wide basis, to processes aimed at achieving total customer satisfaction. Imatron Inc. is primarily engaged in designing, manufacturing, marketing, and supporting high performance computed tomography (CT) scanners based on the Company's proprietary scanning electron beam technology. Ultrafast CT(R) is a registered trademark of Imatron. Imatron's Ultrafast CT scanner is now in use at major medical centers around the world, including The Mayo Clinic, University of Iowa, National Institutes of Health, UCLA, Stanford University, University of Illinois, The Royal Brompton Hospital in London, Tokyo University Hospital, Beijing Hospital and the National University Hospital of Singapore. Imatron's HeartScan Imaging Inc. subsidiary provides Coronary Artery Disease Risk Assessment diagnostic services in a nationwide network of clinics. -0- Except for the historical information contained herein, the matters discussed in this news release may contain forward-looking statements that are based on current expectations and estimates about the industry in which Imatron operates, the estimated impact of certain technological advances, the estimated impact of published research studies on scanner sales and procedures, as well as management's beliefs and assumptions. It is important to note that the Company's actual results could differ materially from those projected in such forward-looking statements. The factors that could cause actual results to differ materially include, among others: failed clinical demonstration of certain asserted technological advantages and diagnostic capabilities; reliance on product distributors; competition in the diagnostic imaging market; failure to improve product reliability or introduce new product models and enhancements; delays in production and difficulty in obtaining components and sub-assemblies from limited sources of supply; inability to meet cash-on-delivery or prepayment terms from vendors; determinations by regulatory and administrative government authorities; patent expiration and denial of patent applications; the high cost of the scanner as compared to commercially available CT scanners; and the risk factors listed from time to time in the Company's Securities and Exchange Commission reports, including their reports on Form 10-K for their current fiscal year. --30--JP/la* RPL/la CONTACT: Imatron Inc., So. San Francisco S. Lewis Meyer, President/CEO Gary Brooks, VP Finance/CFO Lisa Kimberlin, Investor Relations 650/583-9964 or Sitrick And Company, Los Angeles Jeffrey Lloyd/Tony Knight, 310/788-2850